New drug combo shows promise for tough-to-treat lung cancer
NCT ID NCT06448910
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests a new drug, cadonilimab, combined with standard chemotherapy and radiation for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and control the disease. 41 adults who have not had prior treatment are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.